Silverberg M, Longo J, Kaplan A P
J Biol Chem. 1986 Nov 15;261(32):14965-8.
Plasma kallikrein and factor XIa circulate bound to high molecular weight kininogen, and such binding has been reported to protect these enzymes from inactivation by their respective inhibitors. However, this observation is controversial, and the effect of high molecular weight kininogen upon the interaction between kallikrein and C1 inhibitor (C1-INH) has been questioned. We have re-evaluated this reaction and studied the rate of inhibition of kallikrein by C1-INH in the presence and absence of high molecular weight kininogen. The second-order rate constant of inhibition of kallikrein by C1-INH was unaffected by saturating concentrations of high molecular weight kininogen. Our results suggest that although high molecular weight kininogen clearly augments the rate of formation of kallikrein and other enzymes of the contact activation pathway, it has no effect on the rate of enzyme inhibition by C1-INH.
血浆激肽释放酶和因子XIa与高分子量激肽原结合而循环,据报道这种结合可保护这些酶不被其各自的抑制剂灭活。然而,这一观察结果存在争议,高分子量激肽原对激肽释放酶与C1抑制剂(C1-INH)之间相互作用的影响也受到质疑。我们重新评估了这一反应,并研究了在有和没有高分子量激肽原存在的情况下,C1-INH对激肽释放酶的抑制速率。C1-INH对激肽释放酶的抑制二级速率常数不受饱和浓度高分子量激肽原的影响。我们的结果表明,虽然高分子量激肽原明显提高了激肽释放酶和接触激活途径中其他酶的形成速率,但它对C1-INH抑制酶的速率没有影响。